title: [Vortioxetine in the treatment of major depression].
abstract: Notwithstanding the high prevalence, functional burden, negative consequences and risk of chronicity of major depressive disorder, few innovative medications have been developed in recent years for the treatment of this heterogeneous disease. Vortioxetine is a multi-modal antidepressant that functions both as serotonin transporter (SERT) inhibitor and as 5-HT3, 5-HT7 and 5-HT1D receptors antagonist, 5-HT1A receptor agonist and 5-HT1B receptor partial agonist. A recent meta-analysis of 11 randomized, double-blind, placebo controlled, acute (6-8 weeks) treatment studies has demonstrated the efficacy of vortioxetine 5-20 mg/day in the treatment of depression, with an increasing effect associated with increasing dose. Additionally, vortioxetine 5-20 mg/day has shown efficacy on the whole range of depression symptoms (as demonstrated by the improvement of all single-item MADRS scores). Vortioxetine has also been shown effective in the treatment of severe depression and depression with inadequate response to a previous SSRI or SNRI treatment, as well as in the prevention of relapse. In studies designed to assess cognition in depression, vortioxetine showed evidence of improving cognitive performance in patients with acute major depressive disorder. Vortioxetine appears well-tolerated, with very limited effects on weight gain and sexual functioning. The most commonly occurring adverse event (nausea) was generally transitory.
authors.affiliation: Sezione di Psichiatria, Laboratorio di Psichiatria Molecolare, Dipartimento di Neuroscienze Scienze Riproduttive ed Odontostomatologiche, Università di Napoli Federico II.
authors.forename: Andrea
authors.initials: A
authors.lastname: de Bartolomeis
authors.affiliation: Dipartimento di Medicina Molecolare, Università di Siena.
authors.forename: Andrea
authors.initials: A
authors.lastname: Fagiolini
authors.affiliation: AOU San Luigi Gonzaga, Orbassano (TO); Università di Torino.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Maina
mesh_terms: D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy; D003072:Cognition Disorders / Q000188:drug therapy; D003865:Major Depressive Disorder / Q000188:drug therapy*; D004311:Double-Blind Method; D006261:Headache / Q000139:chemically induced; D006801:Humans; D015201:Meta-Analysis as Topic; D009325:Nausea / Q000139:chemically induced; D010879:Piperazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D011985:Receptors, Serotonin / Q000187:drug effects; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D013440:Sulfides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome; D014717:Vertigo / Q000139:chemically induced; D000078784:Vortioxetine
chemical_list: D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D010879:Piperazines; D011985:Receptors, Serotonin; D017367:Selective Serotonin Reuptake Inhibitors; D013440:Sulfides; D000078784:Vortioxetine